cas 869367-33-9|| where to buy 8-chloro-4-(dimethylaminomethylene)-1-(2-fluoro-6-methoxy-phenyl)-3H-2-benzazepin-5-one

製品名:8-chloro-4-(dimethylaminomethylene)-1-(2-fluoro-6-methoxy-phenyl)-3H-2-benzazepin-5-one

IUPAC Name:8-chloro-4-[(dimethylamino)methylidene]-1-(2-fluoro-6-methoxyphenyl)-4,5-dihydro-3H-2-benzazepin-5-one

包装単位	有効在庫	価格（USD）
CM1018162-100mg	in stock	ŤľǪ
CM1018162-250mg	in stock	Ǫƚƚ
CM1018162-500mg	1-2 Weeks	ŌƚƚŌ
CM1018162-1g	1-2 Weeks	ŌǙƚƚ
CM1018162-5g	1-2 Weeks	ƈǙƚƚ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 869367-33-9 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:869367-33-9; 分子式:C20H18ClFN2O2; 融点:-; SMILESコード:COC1=CC=CC(F)=C1C1=NCC(=CN(C)C)C(=O)C2=CC=C(Cl)C=C12; 密度:

: Alisertib; Puma Biotechnology announced the initiation of its ALISertib in CAncer (ALISCA-Lung1) Phase II trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer. The ALISCA-Lung1 trial will enroll up to 60 patients with extensive stage small cell lung cancer who have progressed on or after first-line platinum-based chemotherapy and immunotherapy. The primary endpoint of the trial is objective response rate, with secondary endpoints of duration of response, disease control rate, progression-free survival and overall survival. Based upon the outcomes of the study, Puma anticipates meeting with the FDA to explore the potential for an accelerated approval pathway for alisertib in small cell lung cancer. Alisertib is an orally active and selective Aurora A kinase inhibitor, which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.